Docohexanoic acid (DHA), a dietary n-3 polyunsaturated fatty-acid omega-3 (n-3, PUFA), showed
potential beneficial effects in reducing all-cause mortality in hemodialysis (HD) patients.
This clinical trial aimed to analyze whether DHA supplementation was a modulator of
erythropoietin (EPO) response and inflammation in hemodialysis (HD) patients.
Phase:
N/A
Details
Lead Sponsor:
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal